Clinical Trial Update: Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study evaluating potential drug–drug interactions between AZD1656 and pioglitazone in individuals with Type 2 Diabetes Mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AZD1656
• Actos (Pioglitazone)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED